Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2014
At a glance
- Drugs BMS 986094 (Primary) ; Daclatasvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Nov 2013 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 23 Aug 2012 Status changed from suspended to withdrawn prior to recruitment prior to recruitment.
- 06 Aug 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.